Tuberculosis in India

Competition Heats Up In Molecular Tuberculosis Market According to Kalorama Information

Retrieved on: 
Monday, July 13, 2020
Infectious diseases, Medical specialties, Tuberculosis, World Tuberculosis Day, Tuberculosis in India

ARLINGTON, Va., July 13, 2020 /PRNewswire-PRWeb/ --Molecular diagnostics can be useful in the diagnosis of tuberculosis (TB).

Key Points: 
  • ARLINGTON, Va., July 13, 2020 /PRNewswire-PRWeb/ --Molecular diagnostics can be useful in the diagnosis of tuberculosis (TB).
  • According to WHO statistics, 10 million people fell ill with TB in 2017 and 1.6 million died from the disease.
  • COVID-19 has to some degree affected diagnosis and treatment of all other diseases, and tuberculosis is no exception.
  • Kalorama Information publishes market studies at http://www.kaloramainformation.com .

2020 Market Spotlight on Tuberculosis (TB) - Licensing and Asset Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020
Infectious diseases, Pharmaceutical, Health, Tuberculosis, Infectious diseases, Medicine, Medical specialties, Multi-drug-resistant tuberculosis, Tuberculosis in India

The "Market Spotlight: Tuberculosis (TB)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Tuberculosis (TB)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
  • The publisher estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
  • There have been 17 licensing and asset acquisition deals involving TB drugs during 2015-20.

InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis

Retrieved on: 
Tuesday, June 2, 2020
Tuberculosis, Health, Medicine, Clinical medicine, TB Alliance, Tuberculosis management, Infection, Multi-drug-resistant tuberculosis, Tuberculosis in India

TB Alliance will make use of InveniAIs AI and machine learning platform, AlphaMeld, to identify and accelerate transformative therapies for the management, treatment, and cure of TB, which remains the worlds top infectious disease killer.

Key Points: 
  • TB Alliance will make use of InveniAIs AI and machine learning platform, AlphaMeld, to identify and accelerate transformative therapies for the management, treatment, and cure of TB, which remains the worlds top infectious disease killer.
  • Globally, about 10 million people develop active TB each year and 1.5 million die from their disease.
  • TB bacteria are becoming increasingly resistant to conventional six-month antibiotic treatments, with an estimated 500,000 people developing drug-resistant forms of TB each year.
  • Our mission is to develop and deliver new TB treatments that address the significant unmet needs that TB patients face today, said Nader Fotouhi, Ph.D., Chief Scientific Officer, TB Alliance.

The Global Tuberculosis Drugs Market is expected to grow from USD 1,483.27 Million in 2018 to USD 2,182.39 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.67%

Retrieved on: 
Tuesday, April 28, 2020
Infectious diseases, Medical specialties, Medicine, Tuberculosis, Latent tuberculosis, Tuberculosis management, Tuberculosis in India

On the basis of Disease Type, the Global Tuberculosis Drugs Market is studied across Active TB and Latent TB.

Key Points: 
  • On the basis of Disease Type, the Global Tuberculosis Drugs Market is studied across Active TB and Latent TB.
  • On the basis of Drug Class, the Global Tuberculosis Drugs Market is studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs.
  • What are the factors that affect the growth in the Global Tuberculosis Drugs Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tuberculosis Drugs Market?

The Global Tuberculosis Diagnostics Market is expected to grow from USD 2,394.63 Million in 2018 to USD 3,459.42 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.39%

Retrieved on: 
Tuesday, April 28, 2020
Medicine, Medical specialties, Clinical medicine, Tuberculosis, Mantoux test, Mantoux, Tuberculosis in India, Latent tuberculosis

On the basis of Test Type, the Global Tuberculosis Diagnostics Market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.

Key Points: 
  • On the basis of Test Type, the Global Tuberculosis Diagnostics Market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.
  • What are the factors that affect the growth in the Global Tuberculosis Diagnostics Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tuberculosis Diagnostics Market?
  • What are the modes of entering the Global Tuberculosis Diagnostics Market?

Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec, a First-in-Class Antibiotic for the Treatment of Tuberculosis

Retrieved on: 
Wednesday, March 25, 2020
General Health, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medicine, Clinical medicine, Health, RTT, Health in Africa, Tuberculosis, Rifampicin, Isoniazid, Sputum, Tuberculosis management, Tuberculosis in India, Telacebec (Q203), Qurient

Qurient Co. Ltd. today announced the publication in the New England Journal of Medicine (NEJM) of positive results from the Phase 2 clinical trial for telacebec (Q203), a first-in-class, orally available antibiotic for the treatment of tuberculosis (TB).

Key Points: 
  • Qurient Co. Ltd. today announced the publication in the New England Journal of Medicine (NEJM) of positive results from the Phase 2 clinical trial for telacebec (Q203), a first-in-class, orally available antibiotic for the treatment of tuberculosis (TB).
  • (Graphic: Business Wire)
    TB is a serious bacterial infection that mainly affects the lungs and remains one of the top 10 causes of death worldwide.
  • The Phase 2 clinical study for telacebec (Q203) was a prospective, randomized, open-label trial involving 61 patients with newly diagnosed, rifampicin- and isoniazid-susceptible pulmonary tuberculosis.
  • The primary endpoint data showed a daily increase in the time samples required to become culture positive after sputum inoculation.

QIAGEN’s QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria

Retrieved on: 
Wednesday, February 19, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Medical devices, Infectious diseases, Clinical trials, Tuberculosis, Medicine, Infectious diseases, Medical specialties, Latent tuberculosis, Qiagen, Interferon gamma release assay, QuantiFERON, Tuberculosis in India

QIAGEN has partnered with Nigerias National Tuberculosis & Leprosy Control Program (NTBLCP) to adapt World Health Organisation (WHO) guidelines and provide guidance to healthcare professionals on dealing with latent TB.

Key Points: 
  • QIAGEN has partnered with Nigerias National Tuberculosis & Leprosy Control Program (NTBLCP) to adapt World Health Organisation (WHO) guidelines and provide guidance to healthcare professionals on dealing with latent TB.
  • Nigeria is the first high-burden country to exclusively embrace modern blood tests, called interferon gamma release assays (IGRAs), for latent TB screening of at-risk individuals in tuberculosis control programs.
  • Nigeria is first in Africa to adopt the Global End TB strategy by incorporating TB prevention in their national TB guidelines.
  • To finally provide both TB treatment and prevention for Nigerians is a major step forward towards global health equity and accelerating TB decline in Nigeria.

Global Tuberculosis (TB) Market Spotlight 2019-2027: GlaxoSmithKline Leads Industry Sponsors with the Highest Overall Number of Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Health, Infectious diseases, Tuberculosis, Health, Infectious diseases, Medicine, Clinical trial, Tuberculosis in India, World Tuberculosis Day

It is estimated that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.

Key Points: 
  • It is estimated that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
  • South Africa has a substantial lead in the number of TB clinical trials globally.
  • GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
  • GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.

The anti-tuberculosis therapeutics market is expected to witness a CAGR of approximately 6.0% over the forecast period, 2019

Retrieved on: 
Monday, June 24, 2019
Tuberculosis, Infectious diseases, Medicine, Clinical medicine, Tuberculosis in India, Draft:Tuberculosis in Pakistan

The anti-tuberculosis therapeutics market is expected to witness a CAGR of approximately 6.0% over the forecast period, 2019-2024.

Key Points: 
  • The anti-tuberculosis therapeutics market is expected to witness a CAGR of approximately 6.0% over the forecast period, 2019-2024.
  • - According to the WHO's 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016.
  • The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases.
  • Approximately 50% of these new TB cases were reported in the regions of India, China, and the Russian Federation.

Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends 2017-2027 By Disease Type, Drug Class, Product & End User

Retrieved on: 
Tuesday, June 19, 2018
Tuberculosis, Health, Actinobacteridae, Corynebacterineae, Multi-drug-resistant tuberculosis, Latent tuberculosis, Tuberculosis in India, Extensively drug-resistant tuberculosis

The "Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Tuberculosis (TB) Drugs/Therapeutics Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Some of the prominent trends that the market is witnessing include increased focus on TB vaccine development and rising the emergence of drug-resistant TB.
  • Based on Type, the market is categorized into Latent Tuberculosis, Active Tuberculosis and Drug-resistant Tuberculosis.
  • Depending on Drug Class the market is segregated into First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs and Combination Drugs.